Abgenix's Unattributed VC - II Round

Abgenix raised a round of funding on November 13, 2001.

Abgenix aims to deliver fully human monoclonal antibodies for a range of disease targets, several of which are currently in clinical trials. The company leverages its XenoMouse technology platform to …

Articles about Abgenix's Unattributed VC - II Round: